Last Posted: Sep 03, 2020
- Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
Dummer Reinhard et al. The New England journal of medicine 2020 Sep - Germline HOXB13 G84E mutation carriers and risk to twenty common types of cancer: results from the UK Biobank.
Wei Jun et al. British journal of cancer 2020 Aug - TERT Promoter Mutation as an Independent Prognostic Marker for Poor Prognosis MAPK Inhibitors-Treated Melanoma.
Blateau Pauline et al. Cancers 2020 Aug 12(8) - Effects of health literacy skills, educational attainment, and level of melanoma risk on responses to personalized genomic testing.
Kaphingst Kimberly A et al. Patient education and counseling 2020 Aug - Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA.
Diefenbach Russell J et al. Cancers 2020 Aug 12(8) - High expression of GPNMB indicates an unfavorable prognosis in glioma: Combination of data from the GEO and CGGA databases and validation in tissue microarray.
Feng Xiao et al. Oncology letters 2020 Sep 20(3) 2356-2368 - Comparison of BRAF Mutation Screening Strategies in a Large Real-Life Series of Advanced Melanoma Patients.
Colombino Maria et al. Journal of clinical medicine 2020 Jul 9(8) - Impact of Next Generation Sequencing on Clinical Practice in Oncology in France: Better Genetic Profiles for Patients Improve Access to Experimental Treatments.
Coquerelle Séverine et al. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2020 Jul 23(7) 898-906 - Informing patients about their mutation tests: CDKN2A c.256G>A in melanoma as an example.
Hemminki Kari et al. Hereditary cancer in clinical practice 2020 1815 - Machine learning model to predict oncologic outcomes for drugs in randomized clinical trials.
Schperberg Alexander V et al. International journal of cancer 2020 Aug
.png)
No hay comentarios:
Publicar un comentario